Egetis Therapeutics AB (publ) (FRA:P0F)

Egetis Therapeutics AB Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 23, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	177	219	147	137	108	123
Market Cap Growth	-11.23%	49.44%	7.39%	26.97%	-12.25%	20.18%
Enterprise Value	171	218	139	120	91	107
Last Close Price	0.41	0.59	0.47	0.63	0.59	0.65
PS Ratio	35.23	54.55	28.34	67.42	29.00	30.33
PB Ratio	7.03	5.10	2.99	3.01	2.10	1.96
P/TBV Ratio	7.09	5.14	3.02	3.04	2.13	1.98
EV/Sales Ratio	33.05	54.16	26.91	59.07	24.58	26.41
Debt / Equity Ratio	0.33	0.24	0.21	0.01	0.01	0.01
Net Debt / Equity Ratio	-0.19	-0.47	-0.35	-0.25	-0.26	-0.45
Net Debt / EBITDA Ratio	0.19	0.73	0.61	0.64	1.34	1.60
Net Debt / FCF Ratio	0.23	1.03	0.68	0.72	1.07	2.10
Asset Turnover	0.09	0.06	0.09	0.04	0.06	0.08
Inventory Turnover	45.41	13.65	16.92	219.39	50.34	-
Quick Ratio	0.76	1.83	3.27	2.80	3.85	4.21
Current Ratio	0.80	1.86	3.33	2.98	3.90	4.28
Return on Equity (ROE)	-111.83%	-66.17%	-62.16%	-37.51%	-18.05%	-40.66%
Return on Assets (ROA)	-33.74%	-25.91%	-29.45%	-21.78%	-10.22%	-22.42%
Return on Capital Employed (ROCE)	-91.00%	-54.70%	-47.40%	-38.50%	-19.80%	-27.40%
Earnings Yield	-17.08%	-13.66%	-20.02%	-12.72%	-9.44%	-14.44%
FCF Yield	-11.75%	-9.06%	-17.05%	-11.39%	-11.76%	-10.92%
Buyback Yield / Dilution	-22.32%	-19.57%	-33.86%	-7.97%	-166.96%	-30.54%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.